Recent Quotes (30 days)

You have no recent quotes
chg | %

Promis Neurosciences Inc  

(Public, TSE:PMN)   Watch this stock  
Find more results for TSE:AMF
0.320
-0.005 (-1.54%)
Delayed:   10:21AM EDT
TSE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 0.32 - 0.32
52 week 0.04 - 0.35
Open 0.32
Vol / Avg. 39,182.00/704,201.00
Mkt cap 71.89M
P/E     -
Div/yield     -
EPS -0.02
Shares 200.47M
Beta -1.30
Inst. own     -
Aug 10, 2017
Q2 2017 ProMIS Neurosciences Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
May 9, 2017
Q1 2017 ProMIS Neurosciences Inc Earnings Release
Mar 15, 2017
Q4 2016 Promis Neurosciences Inc Earnings Release
  

Key stats and ratios

Q1 (Mar '17) 2016
Net profit margin -207909.10% -128437.90%
Operating margin -207545.50% -127847.20%
EBITD margin - -127599.30%
Return on average assets -341.14% -326.16%
Return on average equity -640.42% -1032.25%
CDP Score - -

Address

1920 Yonge St Suite 200
TORONTO, ON M4S 3E2
Canada
+1-416-8476898 (Phone)
+1-416-8476899 (Fax)

Website links

Description

ProMIS Neurosciences Inc, formerly Amorfix Life Sciences Ltd, is a Canada-based development-stage biotech company. The Company discovers and develops precision therapeutics with companion diagnostics for early detection and treatment of neurodegenerative diseases, in particular Alzheimer's disease (AD) and amyotrophic lateral sclerosis (ALS). The assays are developed using its technologies, Epitope Protection and AMFIA. It is developing therapies targeting misfolded, neurotoxic forms of Amyloid beta in AD and superoxide dismutase 1 (SOD1) in ALS. The Company focuses to use its platform to discover further targets for precision medicine solutions through identification of target epitopes on other misfolded strains of Amyloid beta. The Company focuses to evaluate targets on misfolded strains of tau, another protein implicated in neurodegenerative diseases, including Alzheimer's. The Company has not generated any product revenues.

Officers and directors

Eugene Williams Executive Chairman of the Board
Elliot Goldstein M.D. President, Chief Executive Officer, Director
Age: 65
Neil Cashman M.D. Co-Founder, Chief Scientific Officer, Director
Daniel E. Geffken CPA Chief Financial Officer
Steven S. Plotkin Ph.D. Chief Physics Officer
Robert Gundel Ph.D. Director
Anthony J. Giovinazzo Director
Richard J. Gregory Ph.D. Director
Age: 58
Johannes M. Roth Independent Director
Age: 36